DOPTELET
LOE Approachingavatrombopag maleate
NDAORALTABLETPriority Review
Approved
May 2018
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
DOPTELET (avatrombopag maleate) is bioavailable, small molecule tpo receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPTELET (avatrombopag maleate) is an oral, bioavailable small molecule TPO receptor agonist approved in 2018 that stimulates megakaryocyte proliferation and platelet production without competing with endogenous TPO. It is indicated for patients with thrombocytopenia who require platelet elevation prior to medical or dental procedures, or those with chronic immune thrombocytopenia.
$96MPart D
LOE Approaching12mo to LOEWith only ~1 year until LOE in July 2027, the brand team is in defensive mode; expect focus on lifecycle extension, patient retention, and transition planning rather than growth.
Mechanism of Action
bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Started Feb 2022
199 enrolled
Immune ThrombocytopeniaITP
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.